文献速递胸部肿瘤放疗

短报告:立体定向消融放疗联合手术治疗早期非小细胞肺癌II期试验(MISSILE-NSCLC)的中期安全性结果

Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC).
PubMed 文献 · Radiat Oncol · 2017-01-27

该II期试验评估新辅助立体定向消融放疗(SABR)后手术能否改善I期非小细胞肺癌(NSCLC)的肿瘤学结局。本文报告前10例完成方案治疗患者的中期安全性分析:急性3-4级毒性发生率为10%,术后90天无死亡。样本量小,尚不能对总体毒性率做出确定性结论。

要点

  • 新辅助SABR后手术的急性3-4级毒性发生率为10%,术后90天无死亡。
  • SABR采用风险适应分次方案(54Gy/3次、55Gy/5次或60Gy/8次),手术计划在10周后进行。
  • 样本量小(10例完成治疗),无法对总体毒性率做出确定性结论。

核心结论

  • 新辅助SABR后手术治疗早期NSCLC的急性3-4级毒性发生率为10%,术后90天无死亡。
  • 因样本量小,尚不能对总体毒性率做出确定性结论。

研究设计与样本

  • II期试验,计划纳入可手术的活检证实T1-2 N0 NSCLC患者。
  • SABR采用风险适应分次方案(54Gy/3次、55Gy/5次或60Gy/8次),手术计划在10周后进行。
  • 报告前10例完成方案治疗患者的中期安全性分析,毒性记录采用CTCAE 4.0版。

主要发现

  • 完成两种治疗的10例患者中,中位年龄70岁(范围54-76),60%为T1期,60%为腺癌,中位FEV1为预测值的73%(范围54-87%)。
  • SABR后至手术的中位时间为10.1周(范围9.3-15.6周),手术方式为肺叶切除8例、楔形切除2例。
  • SABR后中位随访6.3个月,急性3-4级毒性发生率为10%,术后90天无死亡。

临床怎么用

  • 该中期安全性数据可供设计或实施类似新辅助SABR联合手术试验的研究者参考。

局限性

  • 样本量小(10例完成治疗),无法对总体毒性率做出确定性结论。
  • 中位随访仅6.3个月,安全性评估时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: A phase II trial was launched to evaluate if neoadjuvant stereotactic ablative radiotherapy (SABR) before surgery improves oncologic outcomes in patients with stage I non-small cell lung cancer (NSCLC). We report a mandated interim safety analysis for the first 10 patients who completed protocol treatment. Operable patients with biopsy-proven T1-2 N0 NSCLC were eligible. SABR was delivered using a risk-adapted fractionation (54Gy/3 fractions, 55/5 or 60/8). Surgical resection was planned 10 weeks later at a high-volume center (>200 lung cancer resections annually). Patients were imaged with dynamic positron emission tomography-computed tomography scans using 18F-fludeoxyglucose (18F-FDG-PET CT) and dynamic contrast-enhanced CT before SABR and again before surgery. Toxicity was recorded using CTCAE version 4.0. Twelve patients were enrolled between 09/2014 and 09/2015. Two did not undergo surgery, due to patient or surgeon preference; neither patient has developed toxicity or recurrence. For the 10 patients completing both treatments, median age was 70 (range: 54-76), 60% had T1 disease, and 60% had adenocarcinoma. Median FEV1 was 73% predicted (range: 54-87%). Median time to surgery post-SABR was 10.1 weeks (range: 9.3-15.6 weeks). Surgery consisted of lobectomy (n = 8) or wedge resection (n = 2). Median follow-up post-SABR was 6.3 months. After combined treatment, the rate of acute grade 3-4 toxicity was 10%. There was no post-operative mortality at 90 days. The small sample size included herein precludes any definitive conclusions regarding overall toxicity rates until larger datasets are available. However, these data may inform others who are designing or conducting similar trials. TRIAL REGISTRATION: NCT02136355 . Registered 8 May 2014.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Palma DA, Nguyen TK, Kwan K, et al. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC). Radiat Oncol. 2017. PMID: 28129789. doi:10.1186/s13014-017-0770-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。